Connect Sign In
Mast cell disorders are a diverse group of conditions characterized by inappropriate mast cell activation and/or the proliferation and accumulation of abnormal mast cell
ARUP’s Rob Martin (left), a security systems specialist, worked closely with Tjay Mitchell (center) and Joey Edmunds (right) from Stone Security to upgrade ARUP’s securi
Andrew Fletcher, MD, MBA, CPE, CHCQM, FCAP, medical director of Consultative Services at ARUP, has coauthored a study that shows clinicians frequently do not adhere to clinical guidelines.
David Hillyard, MD, ARUP medical director for molecular infectious disease, is among 20 individuals and organizations honored by Utah Business magazine with a Healthcare Hero Award.
Before the pandemic, telemedicine accounted for less than 1% of all physician visits, but that number spiked to over 50% after the appearance of COVID-19 cases in the United States.
The COVID-19 pandemic has forced laboratories to adapt to an ever-shifting landscape that has challenged many foundational practices for laboratory management.
ARUP’s new building will provide a new dining experience and more cuisine options, including eight new food stations instead of the current thr
Perhaps more than ever before, ARUP Blood Services is relying on high school students to help save lives through blood donations, as its usual donor sources have diminished.
A new structure is slowly rising to distinguish the core of University of Utah Research Park. By mid-2021, the building will be the state-of-the-art epicenter of ARUP’s growing operations.
SALT LAKE CITY – ARUP Laboratories today announced that it has received the Supplier Legacy Award from Premier Inc., a leading healthcare improvement company
ARUP Laboratories now offers testing to detect the virus that causes COVID-19 using saliva specimens. The molecular diagnostic test is available with preapproval to ARUP clients nationwide.
As a national EAP program to deliver COVID-19 convalescent plasma to hospitalized patients with COVID-19 concludes, researchers are transitioning to multicenter randomized clinical trials.
